Definition

A preparation of autologous T lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) targeting the enterocyte differentiation antigen guanylyl cyclase C (GUCY2C) that are activated with CAR T cells specific for the CD19 antigen, and coupled to as of yet not fully elucidated signaling domains, with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the autologous GCC-targeting CAR T cells GCC19CART are directed to, specifically bind to, activate, proliferate and release cytokines that promote killing of GCC-expressing tumor cells. GCC is overexpressed in various tumor cell types. The activation of the GCC-targeting T cells by activated CD19 CAR that secrete cytokines, enhances CAR T-cell activation and proliferation, and may increase the T-cell-mediated killing of GCC-expressing tumor cells.